Checkpoint Therapeutics (CKPT)
(Delayed Data from NSDQ)
$2.23 USD
-0.13 (-5.51%)
Updated Sep 24, 2024 03:59 PM ET
Pre-Market: $2.26 +0.04 (1.80%) 8:54 AM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
Cash flow Statements
Fiscal Year End for Checkpoint Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -51.85 | -62.62 | -56.67 | -23.08 | -24.71 |
Depreciation/Amortization & Depletion | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change from Assets/Liabilities | -2.79 | -4.61 | 19.60 | -1.77 | -3.03 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 7.05 | 9.68 | 10.77 | 8.30 | 6.37 |
Net Cash From Operating Activities | -47.59 | -57.55 | -26.31 | -16.55 | -21.37 |
Property & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 44.76 | 17.62 | 41.28 | 33.28 | 27.57 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -4.31 | -2.73 | -1.01 | -2.03 | -2.12 |
Net Cash from Financing Activities | 40.45 | 14.89 | 40.27 | 31.25 | 25.46 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -7.14 | -42.67 | 13.96 | 14.70 | 4.08 |
Cash at Beginning of Period | 12.07 | 54.74 | 40.77 | 26.08 | 22.00 |
Cash at End of Period | 4.93 | 12.07 | 54.74 | 40.77 | 26.08 |
Diluted Net EPS | -3.17 | -7.09 | -7.50 | -4.10 | -7.00 |
Fiscal Year End for Checkpoint Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -17.62 | -10.95 | -51.85 | -32.72 | -27.00 |
Depreciation/Amortization & Depletion | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change from Assets/Liabilities | 2.63 | 3.37 | -2.79 | -1.89 | 6.10 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 2.28 | 1.11 | 7.05 | -6.15 | -5.12 |
Net Cash From Operating Activities | -12.71 | -6.47 | -47.59 | -40.76 | -26.01 |
Property & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 14.00 | 12.79 | 44.76 | 33.62 | 23.62 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -1.26 | 0.00 | -4.31 | -3.16 | -2.26 |
Net Cash from Financing Activities | 12.74 | 12.79 | 40.45 | 30.46 | 21.36 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 0.02 | 6.31 | -7.14 | -10.30 | -4.65 |
Cash at Beginning of Period | 4.93 | 4.93 | 12.07 | 12.07 | 12.07 |
Cash at End of Period | 4.95 | 11.24 | 4.93 | 1.77 | 7.42 |
Diluted Net EPS | -0.18 | -0.33 | -0.94 | -0.29 | -1.05 |